The gut microbiome in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. Issue 12 (17th September 2020)

• Record Type: Journal Article
• Authors: Masetti, Riccardo; Zama, Daniele; Leardini, Davide; Muratore, Edoardo; Turroni, Silvia; Prete, Arcangelo; Brigidi, Patrizia; Pession, Andrea
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 12(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-17
• Subjects: bloodstream infections -- fecal microbiota transplantation -- graft‐versus‐host disease -- gut microbiome -- hematopoietic stem cell transplantation -- pediatric; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28711
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: The gut microbiome (GM) has been associated with different clinical outcomes in the context of allogeneic hematopoietic stem cell transplantation (HSCT). Large multicenter cohort studies in adults have found significant correlations with overall survival, relapse, and incidence of complications. Moreover, GM is already a promising target for therapeutic interventions. However, few data are available in children, a population presenting unique features and challenges. During childhood, the GM evolves rapidly with large structural fluctuations, alongside with the maturation of the immune system. Furthermore, the HSCT procedure presents significant differences in children. These considerations underline the importance of a specific focus on the pediatric setting, and the role of GM and its age‐dependent trajectory in influencing the immunity reconstitution and clinical outcomes. This review provides a comprehensive overview of the available evidence in the field of GM and pediatric HSCT, highlighting age‐specific issues and discussing GM‐based therapeutic approaches.